The effectiveness of peginterferon -alpha2a and the entecavir combination therapy for the chronic hepatitis B patient

The effectiveness of peginterferon -alpha2a and the entecavir combination therapy for the chronic hepatitis B patient - The effectiveness of peginterferon and the entecavir combination therapy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000016275

Enrollment

Registered

2015-01-20

Start date

2015-01-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Hepatitis B

Interventions

PEG-Interferon-alpha2a + Entecavir Entecavir

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: *Genotype C, chronic hepatitis B patients *Written informed consent

Exclusion criteria

Exclusion criteria: *Under 20 years-old *Patients with the past of other IFN and nucleotide analog preparation dosage within the past one year *Patients with a history of the past of hypersensitivity for PEG-IFN-alpha2a or other IFN preparation *Patients with a history of the past of hypersensitivity for biological preparation such as vaccine *Patients with a history of the past of hypersensitivity for an ingredient of Entecavir *Pregnant or lactating patients *Other hepatitis patients like HCV/HDV/HIV *Other chronic liver diseases (autoimmune hepatitis, alcoholic hepatitis, and so on) *Failure of other organs and immunodeficiency patients *Patients with a history or in the presence of severe psychotic depression or other severe psychotic diseases patients *Inappropriate for this study patients

Design outcomes

Primary

Measure	Time frame
To measure the primary and secondary endpoint regarding cases performed the entecavir and peginterferon -alpha2a combination therapy	—

Countries

Japan

Contacts

Public ContactSatoru Hagiwara

Kinki University School of Medicine Department of Gastroenterology and Hepatology

hagi-318@hotmail.co.jp072-366-0221

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026